

Robert P Baughman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6490735/publications.pdf>

Version: 2024-02-01

191
papers

13,590
citations

27035

58
h-index

27587

110
g-index

195
all docs

195
docs citations

195
times ranked

8509
citing authors

#	ARTICLE	IF	CITATIONS
1	Assessment of dyspnea in sarcoidosis using the Baseline Dyspnea Index (BDI) and the Transition Dyspnea Index (TDI). <i>Respiratory Medicine</i> , 2022, 191, 106436.	1.3	9
2	Riociguat for Sarcoidosis-Associated Pulmonary Hypertension. <i>Chest</i> , 2022, 161, 448-457.	0.4	24
3	Management of Advanced Pulmonary Sarcoidosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 205, 495-506.	2.5	21
4	Repository Corticotropin Injection for the Treatment of Pulmonary Sarcoidosis: A Narrative Review. <i>Pulmonary Therapy</i> , 2022, 8, 43-55.	1.1	9
5	WASOG statement on the diagnosis and management of sarcoidosis-associated pulmonary hypertension. <i>European Respiratory Review</i> , 2022, 31, 210165.	3.0	28
6	The lung in autoimmune diseases: sarcoidosis. <i>Handbook of Systemic Autoimmune Diseases</i> , 2022, , 169-188.	0.1	0
7	The association of baseline sarcoidosis measurements with 6-month outcomes that are of interest to patients: Results from the On-line Sarcoidosis Assessment Platform Study (OSAP). <i>Respiratory Medicine</i> , 2022, 196, 106819.	1.3	2
8	The six-minute walk test in sarcoidosis associated pulmonary hypertension: Results from an international registry. <i>Respiratory Medicine</i> , 2022, 196, 106801.	1.3	15
9	Chest high-resolution computed tomography can make higher accurate stages for thoracic sarcoidosis than X-ray. <i>BMC Pulmonary Medicine</i> , 2022, 22, 146.	0.8	7
10	Echocardiographic estimate of pulmonary artery pressure in sarcoidosis patients - real world data from a multi-national study.. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2022, 38, e2021032.	0.2	2
11	World Association for Sarcoidosis and Other Granulomatous Disease (WASOG) Centers of Excellence.. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2022, 38, e2021051.	0.2	0
12	Biologic and advanced immunomodulating therapeutic options for sarcoidosis: a clinical update. <i>Expert Review of Clinical Pharmacology</i> , 2021, 14, 179-210.	1.3	8
13	Unsupervised Clustering Reveals Sarcoidosis Phenotypes Marked by a Reduction in Lymphocytes Relate to Increased Inflammatory Activity on 18FDG-PET/CT. <i>Frontiers in Medicine</i> , 2021, 8, 595077.	1.2	12
14	Management of immunosuppressants in the era of coronavirus disease-2019. <i>Current Opinion in Pulmonary Medicine</i> , 2021, 27, 176-183.	1.2	5
15	Evaluating the Minimal Clinically Important Difference of the Kingâ€™s Sarcoidosis Questionnaire in a Multicenter Prospective Study. <i>Annals of the American Thoracic Society</i> , 2021, 18, 477-485.	1.5	16
16	Advances in predicting patient survival in pulmonary sarcoidosis. <i>Expert Opinion on Orphan Drugs</i> , 2021, 9, 113-122.	0.5	1
17	COVID-19 and Sarcoidosis, Readiness for Vaccination: Challenges and Opportunities. <i>Frontiers in Medicine</i> , 2021, 8, 672028.	1.2	16
18	Phase II Investigation of the Efficacy of Antimycobacterial Therapy in Chronic Pulmonary Sarcoidosis. <i>Chest</i> , 2021, 159, 1902-1912.	0.4	23

#	ARTICLE	IF	CITATIONS
19	ERS clinical practice guidelines on treatment of sarcoidosis. <i>European Respiratory Journal</i> , 2021, 58, 2004079.	3.1	248
20	Health-Related Quality of Life (HRQoL) in Sarcoidosis: Diagnosis, Management, and Health Outcomes. <i>Diagnostics</i> , 2021, 11, 1089.	1.3	30
21	The Value of a Patient Global Assessment in Management of Sarcoidosis. <i>Lung</i> , 2021, 199, 357-362.	1.4	4
22	Detection of early phenotype cardiac sarcoidosis by cardiovascular magnetic resonance. <i>Current Opinion in Pulmonary Medicine</i> , 2021, 27, 478-483.	1.2	1
23	Immune checkpoint inhibitor-associated sarcoidosis: A usually benign disease that does not require immunotherapy discontinuation. <i>European Journal of Cancer</i> , 2021, 158, 208-216.	1.3	33
24	The impact of demographic disparities in the presentation of sarcoidosis: A multicenter prospective study. <i>Respiratory Medicine</i> , 2021, 187, 106564.	1.3	24
25	COVID-19 infections in sarcoidosis: a prospective single center study of 886 sarcoidosis patients. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2021, 38, e2021029.	0.2	2
26	Symptoms, impacts, and suitability of the Pulmonary Arterial Hypertension-Symptoms and Impact (PAH-SYMPACT [®] , [©]) questionnaire in patients with sarcoidosis-associated pulmonary hypertension (SAPH): a qualitative interview study. <i>BMC Pulmonary Medicine</i> , 2021, 21, 365.	0.8	3
27	Scout - sarcoidosis outcomes taskforce. A systematic review of outcomes to inform the development of a core outcome set for pulmonary sarcoidosis. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2021, 38, e2021034.	0.2	2
28	Roflumilast (Daliresp [®]) to reduce acute pulmonary events in fibrotic sarcoidosis: a multi-center, double blind, placebo controlled, randomized clinical trial. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2021, 38, e2021035.	0.2	4
29	Income and Other Contributors to Poor Outcomes in U.S. Patients with Sarcoidosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 201, 955-964.	2.5	57
30	Summary for Clinicians: Clinical Practice Guideline for the Diagnosis and Detection of Sarcoidosis. <i>Annals of the American Thoracic Society</i> , 2020, 17, 1510-1515.	1.5	4
31	Challenges in Cardiac and Pulmonary Sarcoidosis. <i>Journal of the American College of Cardiology</i> , 2020, 76, 1878-1901.	1.2	119
32	Current treatment of sarcoidosis. <i>Current Opinion in Pulmonary Medicine</i> , 2020, 26, 591-597.	1.2	5
33	Advanced Pulmonary Sarcoidosis. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2020, 41, 700-715.	0.8	20
34	Sarcoidosis: Advances in Therapy. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2020, 41, 605-606.	0.8	0
35	Reply to P. B. et al., to Fahim and Rosewarne, and to Reich. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 202, 1322-1324.	2.5	0
36	Mixed Obstructive and Restrictive Ventilatory Defect in Sarcoidosis. <i>Chest</i> , 2020, 158, 1816-1817.	0.4	1

#	ARTICLE	IF	CITATIONS
37	Chest CT scan: The best predictor of mortality in advanced pulmonary sarcoidosis?. <i>Respiratory Medicine</i> , 2020, 170, 106059.	1.3	1
38	Physiological predictors of survival in patients with sarcoidosis-associated pulmonary hypertension: results from an international registry. <i>European Respiratory Journal</i> , 2020, 55, 1901747.	3.1	67
39	When the Game Changes. <i>Chest</i> , 2020, 158, 892-895.	0.4	36
40	Diagnosis and Detection of Sarcoidosis. An Official American Thoracic Society Clinical Practice Guideline. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 201, e26-e51.	2.5	521
41	Clinical phenotyping: role in treatment decisions in sarcoidosis. <i>European Respiratory Review</i> , 2020, 29, 190145.	3.0	25
42	Management of repository corticotrophin injection therapy for pulmonary sarcoidosis: a Delphi study. <i>European Respiratory Review</i> , 2020, 29, 190147.	3.0	11
43	Delphi consensus recommendations for a treatment algorithm in pulmonary sarcoidosis. <i>European Respiratory Review</i> , 2020, 29, 190146.	3.0	92
44	Infection prevention in sarcoidosis: proposal for vaccination and prophylactic therapy. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2020, 37, 87-98.	0.2	8
45	Risk and outcome of COVID-19 infection in sarcoidosis patients: results of a self-reporting questionnaire. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2020, 37, e2020009.	0.2	18
46	Methotrexate in sarcoidosis: hematologic and hepatic toxicity encountered in a large cohort over a six year period. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2020, 37, e2020001.	0.2	6
47	Use of third-line therapies in advanced sarcoidosis. <i>Clinical and Experimental Rheumatology</i> , 2020, 38, 834-840.	0.4	8
48	Management of neurosarcoidosis: a clinical challenge. <i>Current Opinion in Neurology</i> , 2019, 32, 475-483.	1.8	67
49	First patient-centred set of outcomes for pulmonary sarcoidosis: a multicentre initiative. <i>BMJ Open Respiratory Research</i> , 2019, 6, e000394.	1.2	17
50	How the Frequency and Phenotype of Sarcoidosis is Driven by Environmental Determinants. <i>Lung</i> , 2019, 197, 427-436.	1.4	24
51	Endobronchial ultrasound-guided transbronchial needle aspiration in sarcoidosis: Beyond the diagnostic yield. <i>Respirology</i> , 2019, 24, 531-542.	1.3	28
52	Results of the standard set for pulmonary sarcoidosis: feasibility and multicentre outcomes. <i>ERJ Open Research</i> , 2019, 5, 00094-2019.	1.1	5
53	Cardiac sarcoidosis: worse pulmonary function due to left ventricular ejection fraction?. <i>Medicine (United States)</i> , 2019, 98, e18037.	0.4	1
54	Sarcoidosis Involving the Gastrointestinal Tract: Diagnostic and Therapeutic Management. <i>American Journal of Gastroenterology</i> , 2019, 114, 1238-1247.	0.2	36

#	ARTICLE	IF	CITATIONS
55	Advanced sarcoidosis. <i>Current Opinion in Pulmonary Medicine</i> , 2019, 25, 497-504.	1.2	40
56	Presence of onconeural antibodies in sarcoidosis patients with parasarcoidosis syndrome. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2019, 36, 254-260.	0.2	2
57	A composite score to assess treatment response in pulmonary sarcoidosis: the Sarcoidosis Treatment Score (STS). <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2019, 36, 86-88.	0.2	4
58	Geoepidemiological big data approach to sarcoidosis: geographical and ethnic determinants. <i>Clinical and Experimental Rheumatology</i> , 2019, 37, 1052-1064.	0.4	18
59	Pulmonary sarcoidosis. <i>Lancet Respiratory Medicine</i> , 2018, 6, 389-402.	5.2	544
60	Predictors of Mortality in Pulmonary Sarcoidosis. <i>Chest</i> , 2018, 153, 105-113.	0.4	152
61	Higher Priced Older Pharmaceuticals. <i>Chest</i> , 2018, 153, 23-33.	0.4	3
62	Steroids for sarcoidosis: How much and for how long?. <i>Respiratory Medicine</i> , 2018, 138, S5-S6.	1.3	9
63	Sarcoidosis: patient treatment priorities. <i>ERJ Open Research</i> , 2018, 4, 00141-2018.	1.1	41
64	PD-1 up-regulation on CD4 ⁺ T cells promotes pulmonary fibrosis through STAT3-mediated IL-17A and TGF- β 1 production. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	225
65	Short-Term Particulate Air Pollution Exposure is Associated with Increased Severity of Respiratory and Quality of Life Symptoms in Patients with Fibrotic Sarcoidosis. <i>International Journal of Environmental Research and Public Health</i> , 2018, 15, 1077.	1.2	24
66	Clinical features of sarcoidosis associated pulmonary hypertension: Results of a multi-national registry. <i>Respiratory Medicine</i> , 2018, 139, 72-78.	1.3	55
67	Safety of performing transbronchial lung cryobiopsy on hospitalized patients with interstitial lung disease. <i>Respiratory Medicine</i> , 2018, 140, 71-76.	1.3	40
68	Response. <i>Chest</i> , 2018, 153, 1507-1508.	0.4	0
69	Sarcoidosis Diagnostic Score. <i>Chest</i> , 2018, 154, 1052-1060.	0.4	41
70	Sarcoidosis: is cryobiopsy not cool enough? – Authors' reply. <i>Lancet Respiratory Medicine</i> , 2018, 6, e45.	5.2	3
71	Definition and Consensus Diagnostic Criteria for Neurosarcoidosis. <i>JAMA Neurology</i> , 2018, 75, 1546.	4.5	247
72	Treatment of sarcoidosis: grading the evidence. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 677-687.	1.3	66

#	ARTICLE	IF	CITATIONS
73	Circulatory TGF-beta1 is significantly higher in early stage of pulmonary sarcoidosis. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2018, 35, 213-217.	0.2	2
74	Clinical characteristics of patients with bone sarcoidosis. Seminars in Arthritis and Rheumatism, 2017, 47, 143-148.	1.6	76
75	Chronic pulmonary aspergillosis complicating sarcoidosis. European Respiratory Journal, 2017, 49, 1602396.	3.1	66
76	Current concepts regarding calcium metabolism and bone health in sarcoidosis. Current Opinion in Pulmonary Medicine, 2017, 23, 476-481.	1.2	24
77	Repository corticotropin for Chronic Pulmonary Sarcoidosis. Lung, 2017, 195, 313-322.	1.4	75
78	Treatment of sarcoidosis-associated pulmonary hypertension: so close, and yet so far. European Respiratory Journal, 2017, 50, 1701725.	3.1	3
79	Sarcoidosis-Associated Pulmonary Hypertension. Seminars in Respiratory and Critical Care Medicine, 2017, 38, 450-462.	0.8	29
80	Sarcoidosis update. Current Opinion in Pulmonary Medicine, 2017, 23, 432.	1.2	1
81	The complimentary role of transbronchial lung cryobiopsy and endobronchial ultrasound fine needle aspiration in the diagnosis of sarcoidosis. Respiratory Medicine, 2017, 131, 65-69.	1.3	33
82	Cardiac Sarcoidosis. Chest, 2017, 151, 139-148.	0.4	85
83	The indications for the treatment of sarcoidosis: Wells Law. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2017, 34, 280-282.	0.2	21
84	Inter-rater reliability of cutaneous sarcoidosis assessment tools via remote photographic assessment. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2017, 34, 165-169.	0.2	1
85	Biologic therapies in the treatment of sarcoidosis. Expert Review of Clinical Immunology, 2016, 12, 817-825.	1.3	38
86	Sarcoidosis in America. Analysis Based on Health Care Use. Annals of the American Thoracic Society, 2016, 13, 1244-1252.	1.5	257
87	Sarcoidosis: an update on current pharmacotherapy options and future directions. Expert Opinion on Pharmacotherapy, 2016, 17, 2431-2448.	0.9	37
88	Refractory Pulmonary Sarcoidosis. Clinical Pulmonary Medicine, 2016, 23, 67-75.	0.3	43
89	Sarcoidosis patient with lupus pernio and infliximab-induced myositis: Response to Acthar gel. Respiratory Medicine Case Reports, 2016, 17, 5-7.	0.2	7
90	A retrospective pilot study examining the use of Acthar gel in sarcoidosis patients. Respiratory Medicine, 2016, 110, 66-72.	1.3	62

#	ARTICLE	IF	CITATIONS
91	Clinical management of pulmonary sarcoidosis. <i>Expert Review of Respiratory Medicine</i> , 2016, 10, 577-591.	1.0	20
92	Infliximab for chronic cutaneous sarcoidosis: a subset analysis from a double-blind randomized clinical trial. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2016, 32, 289-95.	0.2	25
93	Racial Difference in Sarcoidosis Mortality in the United States. <i>Chest</i> , 2015, 147, 438-449.	0.4	174
94	Response. <i>Chest</i> , 2015, 147, e65-e66.	0.4	0
95	Binding of CXCL8/IL-8 to <i>Mycobacterium tuberculosis</i> Modulates the Innate Immune Response. <i>Mediators of Inflammation</i> , 2015, 2015, 1-11.	1.4	96
96	New treatment strategies for pulmonary sarcoidosis: antimetabolites, biological drugs, and other treatment approaches. <i>Lancet Respiratory Medicine</i> , 2015, 3, 813-822.	5.2	110
97	Treatment of Sarcoidosis. <i>Clinical Reviews in Allergy and Immunology</i> , 2015, 49, 79-92.	2.9	78
98	Sarcoidosis. <i>Clinics in Chest Medicine</i> , 2015, 36, xv.	0.8	4
99	Pulmonary Hypertension in Sarcoidosis. <i>Clinics in Chest Medicine</i> , 2015, 36, 703-714.	0.8	61
100	Sarcoidosis-Associated Pulmonary Hypertension: Diagnosis and Treatment. <i>Advances in Pulmonary Hypertension</i> , 2015, 14, 138-144.	0.1	1
101	Placenta-derived mesenchymal-like cells (PDA-001) as therapy for chronic pulmonary sarcoidosis: a phase 1 study. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2015, 32, 106-14.	0.2	21
102	Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis. <i>European Respiratory Journal</i> , 2014, 44, 1296-1307.	3.1	177
103	Bosentan for Sarcoidosis-Associated Pulmonary Hypertension. <i>Chest</i> , 2014, 145, 810-817.	0.4	144
104	Relapses of sarcoidosis: what are they and can we predict who will get them?. <i>European Respiratory Journal</i> , 2014, 43, 337-339.	3.1	41
105	Medical Therapy of Sarcoidosis. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2014, 35, 391-406.	0.8	30
106	Accuracy of Serial PET-CT Imaging in Systemic Sarcoidosis. <i>Journal of Clinical Imaging Science</i> , 2014, 4, 21.	0.4	7
107	The potential additional benefit of infliximab in patients with chronic pulmonary sarcoidosis already receiving corticosteroids: A retrospective analysis from a randomized clinical trial. <i>Respiratory Medicine</i> , 2014, 108, 189-194.	1.3	39
108	The WASOG Sarcoidosis Organ Assessment Instrument: An update of a previous clinical tool. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2014, 31, 19-27.	0.2	273

#	ARTICLE	IF	CITATIONS
109	Frequency of acute worsening events in fibrotic pulmonary sarcoidosis patients. <i>Respiratory Medicine</i> , 2013, 107, 2009-2013.	1.3	58
110	Established and experimental medical therapy of pulmonary sarcoidosis. <i>European Respiratory Journal</i> , 2013, 41, 1424-1438.	3.1	109
111	Nicotine Treatment Improves Toll-Like Receptor 2 and Toll-Like Receptor 9 Responsiveness in Active Pulmonary Sarcoidosis. <i>Chest</i> , 2013, 143, 461-470.	0.4	58
112	Sarcoidosis, Fatigue, and Sleep Apnea. <i>Chest</i> , 2013, 144, 1976-1977.	0.4	2
113	Liver-test abnormalities in sarcoidosis. <i>European Journal of Gastroenterology and Hepatology</i> , 2012, 24, 17-24.	0.8	97
114	An Official American Thoracic Society Clinical Practice Guideline: The Clinical Utility of Bronchoalveolar Lavage Cellular Analysis in Interstitial Lung Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012, 185, 1004-1014.	2.5	832
115	Pulmonary manifestations of sarcoidosis. <i>Presse Medicale</i> , 2012, 41, e289-e302.	0.8	45
116	Therapy for sarcoidosis: evidence-based recommendations. <i>Expert Review of Clinical Immunology</i> , 2012, 8, 95-103.	1.3	64
117	A Concise Review of Pulmonary Sarcoidosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2011, 183, 573-581.	2.5	426
118	Survival in Sarcoidosis-Associated Pulmonary Hypertension. <i>Chest</i> , 2010, 138, 1078-1085.	0.4	213
119	Significant CD4, CD8, and CD19 Lymphopenia in Peripheral Blood of Sarcoidosis Patients Correlates with Severe Disease Manifestations. <i>PLoS ONE</i> , 2010, 5, e9088.	1.1	105
120	Upper airway.4: Sarcoidosis of the upper respiratory tract (SURT). <i>Thorax</i> , 2010, 65, 181-186.	2.7	63
121	Ocular Sarcoidosis. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2010, 31, 452-462.	0.8	84
122	Sarcoidosis. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2010, 31, 373-374.	0.8	3
123	Changes in Chest Roentgenogram of Sarcoidosis Patients During a Clinical Trial of Infliximab Therapy. <i>Chest</i> , 2009, 136, 526-535.	0.4	98
124	The Use of Carbapenems in the Treatment of Serious Infections. <i>Journal of Intensive Care Medicine</i> , 2009, 24, 230-241.	1.3	48
125	Preface. <i>Clinics in Chest Medicine</i> , 2008, 29, xiii-xiv.	0.8	0
126	Treatment of Sarcoidosis. <i>Clinics in Chest Medicine</i> , 2008, 29, 533-548.	0.8	165

#	ARTICLE	IF	CITATIONS
127	Chronic Facial Sarcoidosis Including Lupus Pernio. American Journal of Clinical Dermatology, 2008, 9, 155-161.	3.3	45
128	Six-Minute Walk Test and Health Status Assessment in Sarcoidosis. Chest, 2007, 132, 207-213.	0.4	178
129	Novel Therapies for Sarcoidosis. Seminars in Respiratory and Critical Care Medicine, 2007, 28, 128-133.	0.8	21
130	Technical Aspects of Bronchoalveolar Lavage: Recommendations for a Standard Procedure. Seminars in Respiratory and Critical Care Medicine, 2007, 28, 475-485.	0.8	116
131	Six-minute walk test in managing and monitoring sarcoidosis patients. Current Opinion in Pulmonary Medicine, 2007, 13, 439-444.	1.2	43
132	Evidence-based therapy for cutaneous sarcoidosis. Clinics in Dermatology, 2007, 25, 334-340.	0.8	80
133	Sarcoidosis. Clinics in Dermatology, 2007, 25, 231.	0.8	5
134	Pulmonary hypertension associated with sarcoidosis. Arthritis Research and Therapy, 2007, 9, S8.	1.6	42
135	Infliximab Therapy in Patients with Chronic Sarcoidosis and Pulmonary Involvement. American Journal of Respiratory and Critical Care Medicine, 2006, 174, 795-802.	2.5	629
136	The National Institutes of Health Blueprint for Neuroscience Research. Journal of Neuroscience, 2006, 26, 10329-10331.	1.7	20
137	Pulmonary hypertension in sarcoidosis. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2006, 23, 108-16.	0.2	78
138	RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF INFlixIMAB IN PATIENTS WITH CHRONIC PULMONARY SARCOIDOSIS. Chest, 2005, 128, 202S.	0.4	106
139	Diagnosis of ventilator-associated pneumonia. Microbes and Infection, 2005, 7, 262-267.	1.0	14
140	Considerations in the Choice and Administration of Agents for Empiric Antimicrobial Therapy. Surgical Infections, 2005, 6, s-71-s-82.	0.7	4
141	Microbiologic Diagnosis of Ventilator-Associated Pneumonia. Clinics in Chest Medicine, 2005, 26, 81-86.	0.8	5
142	Considerations in the choice and administration of agents for empiric antimicrobial therapy. Surgical Infections, 2005, 6 Suppl 2, S-71-82.	0.7	0
143	Interpretation of the Wright-Giemsa Stained Bronchoalveolar Lavage Specimen. Laboratory Medicine, 2004, 35, 553-557.	0.8	4
144	Closure Operators and Lattice Extensions. Order, 2004, 21, 43-48.	0.3	51

#	ARTICLE	IF	CITATIONS
145	Newer Therapies for Cutaneous Sarcoidosis. American Journal of Clinical Dermatology, 2004, 5, 385-394.	3.3	35
146	Pulmonary sarcoidosis. Clinics in Chest Medicine, 2004, 25, 521-530.	0.8	89
147	Sarcoidosis. Lancet, The, 2003, 361, 1111-1118.	6.3	682
148	Tumour Necrosis Factor in Sarcoidosis and its Potential for Targeted Therapy. BioDrugs, 2003, 17, 425-431.	2.2	77
149	Ventilator-Associated Pneumonia Patients who Do Not Reduce Bacteria from the Lungs have a Worse Prognosis. Journal of Intensive Care Medicine, 2003, 18, 269-274.	1.3	62
150	Role of Liver Function Tests in Detecting Methotrexate-Induced Liver Damage in Sarcoidosis. Archives of Internal Medicine, 2003, 163, 615.	4.3	60
151	Diagnosis of ventilator-associated pneumonia. Current Opinion in Critical Care, 2003, 9, 397-402.	1.6	25
152	Nonbronchoscopic evaluation of ventilator-associated pneumonia. Seminars in Respiratory Infections, 2003, 18, 95-102.	1.3	5
153	Therapy for Extrapulmonary Sarcoidosis. Seminars in Respiratory and Critical Care Medicine, 2002, 23, 589-596.	0.8	17
154	Extrapulmonary Sarcoidosis. Seminars in Respiratory and Critical Care Medicine, 2002, 23, 503-504.	0.8	2
155	Therapeutic options for sarcoidosis: new and old. Current Opinion in Pulmonary Medicine, 2002, 8, 464-469.	1.2	52
156	Thalidomide for Chronic Sarcoidosis. Chest, 2002, 122, 227-232.	0.4	202
157	Surfactant Replacement for Ventilator-Associated Pneumonia: A Preliminary Report. Respiration, 2002, 69, 57-62.	1.2	10
158	Antibiotic resistance in the intensive care unit. Current Opinion in Critical Care, 2002, 8, 430-434.	1.6	8
159	The challenge of translational researchâ€”a perspective from the NINDS. Nature Neuroscience, 2002, 5, 1029-1030.	7.1	14
160	Can persistent tumor necrosis factor release lead to refractory sarcoidosis?. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2002, 19, 164-6.	0.2	6
161	Use of fluticasone in acute symptomatic pulmonary sarcoidosis. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2002, 19, 198-204.	0.2	54
162	Utility of a Lung Biopsy for the Diagnosis of Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2001, 164, 193-196.	2.5	525

#	ARTICLE	IF	CITATIONS
163	A ventrodorsal GABA gradient in the embryonic retina prior to expression of glutamate decarboxylase. <i>Neuroscience</i> , 1997, 79, 863-869.	1.1	17
164	Distinct Muscarinic Receptor Subtypes Suppress Excitatory and Inhibitory Synaptic Responses in Cortical Neurons. <i>Journal of Neurophysiology</i> , 1997, 77, 709-716.	0.9	90
165	GABAergic Transcallosal Neurons in Developing Rat Neocortex. <i>European Journal of Neuroscience</i> , 1997, 9, 1137-1143.	1.2	38
166	Immunosuppressant Therapy for Idiopathic Pulmonary Fibrosis. <i>BioDrugs</i> , 1996, 6, 431-442.	0.7	6
167	Agent Orange and the Vietnamese: the persistence of elevated dioxin levels in human tissues.. <i>American Journal of Public Health</i> , 1995, 85, 516-522.	1.5	116
168	Vestibular primary afferent projection to the cerebellum of the rabbit. <i>Journal of Comparative Neurology</i> , 1993, 327, 521-534.	0.9	107
169	Dendritic domains of medium spiny neurons in the primate striatum: Relationships to striosomal borders. <i>Journal of Comparative Neurology</i> , 1993, 337, 614-628.	0.9	44
170	Muscarinic M3 receptors inhibit a leak conductance in rat corticocallosal neurons. <i>NeuroReport</i> , 1992, 3, 889-892.	0.6	11
171	Cholinergic Innervation of the Cerebellum of the Rat by Secondary Vestibular Afferents. <i>Annals of the New York Academy of Sciences</i> , 1992, 656, 566-579.	1.8	30
172	Cholinergic innervation of the cerebellum of rat, rabbit, cat, and monkey as revealed by choline acetyltransferase activity and immunohistochemistry. <i>Journal of Comparative Neurology</i> , 1992, 317, 233-249.	0.9	118
173	Secondary vestibular cholinergic projection to the cerebellum of rabbit and rat as revealed by choline acetyltransferase immunohistochemistry, retrograde and orthograde tracers. <i>Journal of Comparative Neurology</i> , 1992, 317, 250-270.	0.9	152
174	Novel antigenic determinant expressed in neurons of the dorsolateral hypothalamus in rat and human. <i>Journal of Neuroscience Research</i> , 1992, 31, 715-723.	1.3	1
175	Both NMDA and non-NMDA subtypes of glutamate receptors are concentrated at synapses on cerebral cortical neurons in culture. <i>Neuron</i> , 1991, 7, 593-603.	3.8	170
176	Intrastriatal grafts derived from fetal striatal primordia: II. Reconstitution of cholinergic and dopaminergic systems. <i>Journal of Comparative Neurology</i> , 1990, 295, 1-14.	0.9	69
177	Projections to the pontine nuclei from choline acetyltransferase-like immunoreactive neurons in the brainstem of the cat. <i>Journal of Comparative Neurology</i> , 1990, 300, 183-195.	0.9	12
178	Partitioning of 2,3,7,8-chlorinated dibenzo-p-dioxins and dibenzofurans between adipose tissue and plasma lipid of 20 Massachusetts Vietnam veterans. <i>Chemosphere</i> , 1990, 20, 951-958.	4.2	35
179	An anatomical study of cholinergic innervation in rat cerebral cortex. <i>Neuroscience</i> , 1988, 25, 457-474.	1.1	391
180	Choline acetyltransferase immunocytochemistry of Edinger-Westphal and ciliary ganglion afferent neurons in the cat. <i>Brain Research</i> , 1987, 423, 293-304.	1.1	27

#	ARTICLE	IF	CITATIONS
181	Cholinergic Innervation in Cerebral Cortex. <i>Cerebral Cortex</i> , 1987, , 129-160.	0.6	18
182	Cholinergic neuropil of the striatum observes striosomal boundaries. <i>Nature</i> , 1986, 323, 625-627.	13.7	178
183	Decreased phosphatidylcholine in the lung fluid of patients with sarcoidosis. <i>Lipids</i> , 1985, 20, 496-499.	0.7	16
184	Two types of cholinergic innervation in cortex, one co-localized with vasoactive intestinal polypeptide. <i>Nature</i> , 1984, 309, 153-155.	13.7	362
185	Development of Cholinergic and Amino Acid Neurotransmitter Systems in the Chick Retina. <i>Cell and Developmental Biology of the Eye</i> , 1982, , 47-56.	0.1	0
186	Development of Cholinergic and Amino Acid Neurotransmitter Systems in the Chick Retina. <i>Cell and Developmental Biology of the Eye</i> , 1982, , 47-56.	0.1	0
187	Aspartate and glutamate as possible neurotransmitters of cells in layer 6 of the visual cortex. <i>Nature</i> , 1980, 287, 848-850.	13.7	109
188	The Cholinergic System in the Chicken Retina: Cellular Localization and Development. , 1979, , 421-431.		4
189	Different time course of development for high-affinity choline uptake and choline acetyltransferase in the chick retina.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1978, 75, 2525-2529.	3.3	33
190	Biochemical characterization and cellular localization of the cholinergic system in the chicken retina. <i>Brain Research</i> , 1977, 138, 469-485.	1.1	188
191	Diagnosis of Pneumonia in Immunocompromised Patient. , 0, , 53-93.		1